EuroPharma Today

Business and Financial News, In Brief

Josh — Mon, 29 Apr 2013 09:58:22 PDT

Amgen hits a snag after a long bull run; an NEJM letter provokes a response from Biogen Idec; AstraZeneca is troubled generics; Europe freezes, and so does a manufacturing facility.

Germany’s IQWiG Approves Eliquis For AF, But Restricts Its Indication

Josh — Mon, 08 Apr 2013 11:21:39 PDT

Germany’s HTA IQWiG has approved Bristol/Pfizer’s Eliquis (apixaban) for atrial fibrillation but restricted the oral anticoagulant’s indication, leaving a potential gap for its rivals to fill.

Xalkori And Inlyta: NICE Pans Two Pfizer Oncology Drugs In Two Days

Josh — Mon, 01 Apr 2013 08:34:46 PDT

Britain’s NICE has rejected Pfizer’s Xalkori (crizotinib) for lung cancer and Inlyta (axitinib) for kidney carcinoma within two days of each other, putting drug discounts back in the spotlight.

Ariad’s Iclusig Cleared For European Approval By CHMP

Josh — Mon, 25 Mar 2013 07:58:45 PDT

Europe's top scientific advisory panel, CHMP, granted positive opinions for Ariad's new leukemia therapy Iclusig, Gilead's four-drug HIV therapy, Stribild and Baxter's subcutaneous IgG formulation, HyQvia, at its March 2013 meeting,

Europe Transparency Initiatives May Aid Progress Toward Adaptive Licensing Systems

Josh — Mon, 18 Mar 2013 13:06:28 PDT

Industry and regulators are showing more interest in implementing adaptive licensing in Europe. Both sides agree that increased trust and transparency could be stepping stones towards this goal.

CEO Initiative Aims To Reduce Development Time For Alzheimer’s Drugs

Josh — Mon, 11 Mar 2013 07:58:09 PDT

A group of CEOs from Big Pharma, biotech and finance companies have joined forces with philanthropists and health care policy makers to call for a global action plan against Alzheimer's disease.

HIV Deal Between MPP And ViiV Healthcare Offers Future IP Blueprint

Josh — Mon, 04 Mar 2013 14:20:50 PST

An alliance between the Medicines Patent Pool and ViiV Healthcare to supply HIV drugs to the developing world could form a framework for future IP exchanges between originators and generics firms.

EMA’s CHMP Sets Back Vivus’ Qsiva For At Least Two Years In Europe

Josh — Mon, 25 Feb 2013 08:16:48 PST

The EMA has rejected Vivus’ Qsiva for obesity for the second time, citing potential long-term health issues and probably delaying the product’s European launch for at least two years.

Germany May Need To Jump Start Its Stagnant Biosimilars Market

Josh — Mon, 11 Feb 2013 08:29:12 PST

Biosimilars have hit a snag in Germany that neither health insurers nor doctors want to remove, making it likely the government there may need to intervene if cost savings goals from use of such new medicines are to be achieved.

Fourth Quarter Earnings Calls, In Brief

Josh — Mon, 04 Feb 2013 07:51:56 PST

Vertex/FDA in discussions on “breakthrough therapies”; Ipsen earnings hurting in EU; Pfizer discusses biosimilars; Krka likes emerging markets; Novo sees GLP-1 market competition stiffening.